CLNN Clene Inc

Price (delayed)

$5.87

Market cap

$75.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.2

Enterprise value

$91.06M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 19

Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new ...

Highlights
CLNN's gross margin is up by 5% from the previous quarter and by 4.9% YoY
CLNN's quick ratio has soared by 82% from the previous quarter but it is down by 3.3% YoY
CLNN's EPS is up by 21% year-on-year but it is down by 21% since the previous quarter
The revenue has shrunk by 62% YoY and by 33% QoQ
The gross profit has plunged by 60% YoY and by 29% from the previous quarter

Key stats

What are the main financial stats of CLNN

CLNN stock price

How has the Clene stock price performed over time
Intraday
1.91%
1 week
-12.39%
1 month
-27.44%
1 year
46.02%
YTD
0%
QTD
19.07%

Financial performance

How have Clene's revenue and profit performed over time
Revenue
$134,000
Gross profit
$111,000
Operating income
-$21.07M
Net income
-$33.51M
Gross margin
82.8%
Net margin
-25,009.7%
Clene's operating margin has plunged by 97% YoY and by 36% from the previous quarter
The company's net margin has shrunk by 91% QoQ
The revenue has shrunk by 62% YoY and by 33% QoQ
The gross profit has plunged by 60% YoY and by 29% from the previous quarter

Price vs fundamentals

How does CLNN's price correlate with its fundamentals

Growth

What is Clene's growth rate over time

Valuation

What is Clene stock price valuation
P/E
N/A
P/B
N/A
P/S
510.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
679.55
CLNN's EPS is up by 21% year-on-year but it is down by 21% since the previous quarter
The equity has contracted by 7% from the previous quarter
The stock's price to sales (P/S) is 76% more than its last 4 quarters average of 284.4 and 73% more than its 5-year quarterly average of 289.6
The revenue has shrunk by 62% YoY and by 33% QoQ

Efficiency

How efficient is Clene business performance
CLNN's return on sales has dropped by 95% since the previous quarter
The ROA has plunged by 70% YoY and by 34% from the previous quarter
Clene's return on invested capital has decreased by 24% QoQ

Dividends

What is CLNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLNN.

Financial health

How did Clene financials performed over time
The total assets is 46% smaller than the total liabilities
The company's current ratio has surged by 134% QoQ and by 43% YoY
CLNN's quick ratio has soared by 82% from the previous quarter but it is down by 3.3% YoY
Clene's debt to equity has surged by 72% YoY and by 4.9% QoQ
The equity has contracted by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.